Biologic therapies: Lessons from multiple sclerosis

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Inflammatory Bowel Disease 60%
• Tumor Necrosis 50%
• Diseases 30%
• Demyelination 20%
• Cytokine 10%
• Monoclonal Antibody 10%
• Inflammatory Disease 10%
• Rheumatoid Arthritis 10%
• Inflammatory Arthritis 10%
• Crohn's Disease 10%
• Interleukin 17 10%
• Interleukin 12 10%
• Interferon 10%
• Hypovitaminosis D 10%
• Vitamin D Deficiency 10%
• Ustekinumab 10%
• Glatiramer 10%
• Tumor Necrosis Factor Receptor 1 10%
• Tumor Necrosis Factor Receptor 2 10%
• Alpha4 Integrin 10%

Immunology and Microbiology

• Multiple Sclerosis 100%
• Inflammatory Bowel Disease 60%
• Tumor Necrosis Factor Alpha 50%
• Inflammatory Disorder 10%
• Monoclonal Antibody 10%
• Inflammatory Cytokine 10%
• Lymphocyte 10%
• Interleukin 17 10%
• Interferon 10%
• STAT3 10%
• Crohn's Disease 10%
• Interleukin 12 10%
• Tumor Necrosis Factor Receptor 2 10%
• Inflammatory Arthritis 10%
• Ustekinumab 10%
• Tumor Necrosis Factor Receptor 1 10%
• Remyelinization 10%
• Glatiramer Acetate 10%
• Alpha4 Integrin 10%